For Nexavar In Lung Cancer, Focus Moves From First To Second Line

Nexavar failed to meet the primary endpoint of a second Phase III trial in first-line lung cancer, but Bayer/Onyx remain optimistic about prospects for the drug in the disease based on biomarkers.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet